Skip to main content
Oral Solid Dosage (OSD) Contract Manufacturing Market Analysis Asia, North America, Europe, Rest of World (ROW) - China, US, Japan, Canada, Germany - Size and Forecast 2024-2028

Oral Solid Dosage (OSD) Contract Manufacturing Market Analysis Asia, North America, Europe, Rest of World (ROW) - China, US, Japan, Canada, Germany - Size and Forecast 2024-2028

Published: Aug 2024 169 Pages SKU: IRTNTR76012

Market Overview at a Glance

$14.2 B
Market Opportunity
6.84%
CAGR
6.35
YoY growth 2023-2024(%)

Oral Solid Dosage Contract Manufacturing Market Size 2024-2028 

The oral solid dosage (OSD) contract manufacturing market size is forecast to increase by USD 14.2 billion at a CAGR of 6.84% between 2023 and 2028. The market is experiencing significant growth due to several key factors. With the aging population, there is a rising demand for various OSD formulations, including geriatric-specific treatments in the form of granules, powders, and sachets. Stringent regulatory requirements mandate high levels of physical and chemical stability, making it essential for companies to invest in cutting-edge technologies like nano milling, 3D printing technology, and agile manufacturing processes. Additionally, there is an increasing preference for advanced delivery systems such as dry powder inhalers and lozenges. Physical stability and package design are crucial considerations for OSD manufacturers to ensure effective treatment and transportation. Capacity utilization and patent expiry are also driving market growth, as more US FDA-approved manufacturing facilities come online to meet the increasing demand for generic drugs. However, challenges remain, including regulatory compliance and ensuring consistent product quality. To stay competitive, OSD contract manufacturers must continuously innovate and invest in technology to meet the evolving needs of their customers.

Oral Solid Dosage (OSD) Contract Manufacturing Market Size

 Request Free Sample

The market is a significant segment within the pharmaceutical industry, focusing on the production of tablets, capsules, and other oral solid forms of drugs. This market caters to various needs, including the development of novel formulations for large molecule counterparts and addressing medication adherence problems. Patient-centric solutions are increasingly becoming essential in the OSD market. Modified oral solid formulations, including prolonged release dosage forms, controlled release dosage forms, and sustained release dosage forms, are designed to improve drug delivery by maintaining therapeutic levels over an extended period, enhancing patient compliance and treatment outcomes. One such solution is Disintegrating Tablets (ODTs), which offer advantages like faster disintegration and improved bioavailability. These tablets are particularly beneficial for patients who struggle with swallowing traditional solid dosage forms.

Moreover, contract manufacturing companies play a crucial role in the OSD market, providing specialized solid doses for drug developers. These companies offer multidisciplinary expertise in formulation development, production, and quality control, ensuring the production of high-quality OSDs. The manufacturing of OSDs, including tablets and capsules, requires addressing challenges such as API solubility and bioavailability. Contract manufacturing companies employ advanced technologies and techniques to optimize these aspects, ensuring the efficacy and safety of the final product. The market caters to various sectors, including pediatric populations, for whom specialized formulations are essential. Contract manufacturing companies offer solutions tailored to these populations, ensuring the production of age-appropriate dosage forms and flavors.

Furthermore, combination products, which consist of a drug and a device, are gaining popularity in the OSD market. Contract manufacturing companies provide expertise in the production of these complex formulations, ensuring compliance with stringent regulatory requirements. The OSD market also caters to the needs of drug developers working with highly potent APIs. Contract manufacturing companies offer solutions to handle these substances safely and effectively, ensuring the production of high-quality OSDs. Early development formulations are another area where contract manufacturing companies excel. These companies offer services from preclinical development through to commercial production, ensuring a seamless transition from lab to market.

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

  • End-user
    • Large-size companies
    • Small and medium size companies
    • Startups and generic pharmaceutical companies
  • Product
    • Tablets
    • Capsules
    • Powders
    • Granules and others
  • Geography
    • Asia
      • China
      • Japan
    • North America
      • Canada
      • US
    • Europe
      • Germany
    • Rest of World (ROW)

By End-user Insights

The large-size companies segment is estimated to witness significant growth during the forecast period. The market has experienced significant growth in the past 25 years, particularly among large pharmaceutical companies. These companies, also known as big pharma, often have separate divisions dedicated to producing OSD forms. Outsourcing to a Contract Manufacturing Organization (CMO) allows these companies to expand their technological resources without incurring higher overhead costs. OSD forms, including tablets and capsules, require complex manufacturing processes. Chemical stability is crucial during production to ensure the dosing accuracy and effectiveness of the medication. Coating methods, such as enteric coating and film coating, are used to improve swallowing and modify color. Shape modification and color modification are also important for patient compliance and market differentiation.

Furthermore, production costs, toxicity, quality deviations, utility disruptions, and transportation disruptions are challenges that CMOs must address to maintain the highest standards in OSD manufacturing. Pharmaceutical clients rely on CMOs to produce high-quality OSD forms for both clinical and commercial-stage manufacturing. The increasing demand for generic drugs and biologics, the capital-intensive nature of the pharmaceutical industry, and the complex manufacturing requirements make CMOs an essential partner for big pharma.

Oral Solid Dosage (OSD) Contract Manufacturing Market Size

Get a glance at the market share of various segments Request Free Sample

The large-size companies segment was valued at USD 15.10 billion in 2018 and showed a gradual increase during the forecast period.

Regional Insights

Asia is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Oral Solid Dosage (OSD) Contract Manufacturing Market Share by Geography

For more insights on the market share of various regions Request Free Sample

The Asian market is projected to experience substantial expansion over the forecast period. This growth can be attributed to the substantial market penetration of generic medications and the rising adoption of sophisticated technologies in emerging economies, such as India and China. India is projected to be the most rapidly expanding CMO market due to its cost-effective manufacturing solutions. However, China presently leads the CMO market in Asia and is anticipated to maintain its dominance throughout the forecast period. Both China and India are increasingly preferred by companies due to their cost advantages compared to developed countries in Europe and North America. Advanced technologies, including nano milling and 3D printing, are being employed in agile, responsive, and reproducing manufacturing processes to reduce operating costs, enhance product quality, and expedite time to market. These factors collectively contribute to the strong growth of the Asian OSD contract manufacturing market.

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Market Driver

Patent expiry and increasing demand for generic drugs is the key driver of the market. The market encompasses the production of novel formulations in the form of tablets and capsules for various drugs, including their large molecule counterparts. This sector is experiencing significant growth due to the increasing focus on patient-centric solutions that address medication adherence issues. One such innovation is disintegrating tablets (ODTs), which offer improved convenience and compliance. Furthermore, the development of combination products and addressing API solubility challenges are other key trends driving market expansion. The generic drugs industry is thriving due to the increasing need to reduce healthcare costs. Governments worldwide are advocating for the use of affordable generic medications.

Furthermore, in emerging markets like South Korea, over 50 patents affecting approximately 150 pharmaceutical products are set to expire in 2023, providing ample opportunities for OSD contract manufacturers. In the United States, the OSD Contract Manufacturing Market is witnessing substantial growth due to the increasing demand for cost-effective and efficient drug production solutions. The market is driven by the need for novel formulations, addressing patient compliance issues, and the development of combination products. The focus on improving medication adherence through innovative formulations and the production of ODTs is expected to fuel market growth. Additionally, the ongoing trend of API solubility enhancement is a significant factor contributing to market expansion.

Market Trends

An increasing number of US FDA-approved manufacturing facilities is the upcoming trend in the market. The market encounters challenges with capacity utilization, a critical factor determining the production output of a manufacturing unit compared to its established capacity. Capacity utilization plays a significant role in the production of various therapeutic formulations, including granules, powders, sachets, lozenges, and dry powder inhalers.

Furthermore, approximately 35% of Contract Manufacturing Organizations (CMOs) encounter minor constraints, such as time, cost, and resource-related issues, during the manufacturing process. Conversely, 20% of CMOs face moderate to severe constraints, impacting the physical stability and transportation of these OSD treatments. Ensuring optimal capacity utilization is essential for maintaining treatment quality and meeting the growing demands of the geriatric population, who rely on these formulations for various health conditions.

Market Challenge

Capacity utilization and other constraints is a key challenge affecting the market growth. The market is a critical sector in the pharmaceutical industry, catering to the needs of drug developers by producing specialized solid doses. This process involves ensuring optimal bioavailability of drugs, which can be challenging due to the complexities of manufacturing highly potent APIs and early development formulations. Contract manufacturing companies require multidisciplinary expertise to navigate stringent regulatory requirements and deliver complex formulations.

Furthermore, capacity utilization is a significant concern in this market, with approximately 35% of contract manufacturing organizations (CMOs) encountering minor constraints, such as time, cost, and resources, during the manufacturing process. Meanwhile, 20% of CMOs face moderate to major constraints due to capacity limitations. Meeting the needs of the pediatric population, another crucial aspect of the OSD market, adds to the complexity of the manufacturing process. To remain competitive, CMOs must maintain high levels of efficiency and quality, making it essential to work with multiple suppliers and stay updated on the latest industry trends.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Oral Solid Dosage (OSD) Contract Manufacturing Market Share by Geography

 Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc: The company offers oral solid dosage contract manufacturing services such as blister packaging and strip packaging.

The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

  • Acino International AG
  • Aenova Holding GmbH
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Corden Pharma International GmbH
  • Inglasia Pharma Solutions
  • Jubilant Pharmova Ltd.
  • Koninklijke DSM NV
  • Lonza Group Ltd.
  • Merck KGaA
  • NextPharma GmbH
  • Perkin Elmer Inc.
  • Piramal Enterprises Ltd.
  • Pyramid Laboratories Inc.
  • Recipharm AB
  • Siegfried Holding AG
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

The market encompasses the production of tablets, capsules, and other specialized solid doses of drugs for various populations, including those with novel formulations for large molecule counterparts. Contract manufacturing companies play a crucial role in addressing the medication adherence problem by providing patient-centric solutions. Oral solids, such as disintegrating tablets (ODTs), combination products, and granules, are increasingly popular due to their improved bioavailability, ease of administration, and innovative packaging solutions that enhance convenience and patient compliance. API solubility and bioavailability are critical factors in OSD manufacturing, requiring multidisciplinary expertise from drug developers and contract manufacturing companies.

Furthermore, the OSD market caters to various populations, including pediatric and geriatric, with formulations tailored to their specific needs. Pediatric and geriatric drugs, anti-abuse drugs, controlled release drugs, and taste-masked drugs are among the niche enabling technologies that contract manufacturing companies offer. Production costs, toxicity, quality deviations, and transportation disruptions are common challenges faced by contract manufacturing companies in the highly competitive market. To mitigate these challenges, companies employ cost-effective manufacturing methods, such as batch manufacturing and continuous manufacturing, and responsive manufacturing processes that minimize bottlenecks and ensure timely delivery. Investment costs and operating costs are significant factors in the market. Product quality, time to market, and patient safety are top priorities for drug developers and contract manufacturing companies, making it essential to maintain high standards throughout the manufacturing process. The market for OSDs is vast and diverse, encompassing best-selling pharmaceuticals, small molecules, and Biologics Contract Development and Manufacturing Organization (CDMO), making it a dynamic and exciting field for innovation and growth.

Market Scope

Report Coverage

Details

Page number

169

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 6.84%

Market Growth 2024-2028

USD 14.2 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.35

Regional analysis

Asia, North America, Europe, and Rest of World (ROW)

Performing market contribution

Asia at 45%

Key countries

China, US, Japan, Canada, and Germany

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Acino International AG, Aenova Holding GmbH, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., Corden Pharma International GmbH, Inglasia Pharma Solutions, Jubilant Pharmova Ltd., Koninklijke DSM NV, Lonza Group Ltd., Merck KGaA, NextPharma GmbH, Perkin Elmer Inc., Piramal Enterprises Ltd., Pyramid Laboratories Inc., Recipharm AB, Siegfried Holding AG, Thermo Fisher Scientific Inc., and Viatris Inc.

Market dynamics

Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period

Customization purview

If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request Free Sample

What are the Key Data Covered in this Market Research and Growth Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
  • Precise estimation of the size of the market  and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming market growth and trends and changes in consumer behaviour
  • Growth of the market across Asia, North America, Europe, and Rest of World (ROW)
  • Thorough analysis of the market's competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Global Market Characteristics
    • Executive Summary - Chart on Market by Geography
    • Executive Summary - Chart on Market Segmentation by End-user
    • Executive Summary - Chart on Market Segmentation by Product
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Parent Market
    • Data Table on - Parent Market
  • 2.2 Market characteristics
    • Market characteristics analysis
  • 2.3 Value chain analysis
    • Value Chain Analysis

3 Market Sizing

  • 3.1 Market definition
    • Offerings of companies included in the market definition
  • 3.2 Market segment analysis
    • Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global Oral Solid Dosage (OSD) Contract Manufacturing Market 2018 - 2022
      • Historic Market Size - Data Table on Global Oral Solid Dosage (OSD) Contract Manufacturing Market 2018 - 2022 ($ billion)
    • 4.2 End-user segment analysis 2018 - 2022
      • Historic Market Size - End-user Segment 2018 - 2022 ($ billion)
    • 4.3 Product segment analysis 2018 - 2022
      • Historic Market Size - Product Segment 2018 - 2022 ($ billion)
    • 4.4 Geography segment analysis 2018 - 2022
      • Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country segment analysis 2018 - 2022
      • Historic Market Size - Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Bargaining power of buyers - Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Threat of new entrants - Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Threat of substitutes - Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Threat of rivalry - Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Chart on End-user - Market share 2023-2028 (%)
      • Data Table on End-user - Market share 2023-2028 (%)
    • 6.2 Comparison by End-user
      • Chart on Comparison by End-user
      • Data Table on Comparison by End-user
    • 6.3 Large-size companies - Market size and forecast 2023-2028
      • Chart on Large-size companies - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Large-size companies - Market size and forecast 2023-2028 ($ billion)
      • Chart on Large-size companies - Year-over-year growth 2023-2028 (%)
      • Data Table on Large-size companies - Year-over-year growth 2023-2028 (%)
    • 6.4 Small and medium size companies - Market size and forecast 2023-2028
      • Chart on Small and medium size companies - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Small and medium size companies - Market size and forecast 2023-2028 ($ billion)
      • Chart on Small and medium size companies - Year-over-year growth 2023-2028 (%)
      • Data Table on Small and medium size companies - Year-over-year growth 2023-2028 (%)
    • 6.5 Startups and generic pharmaceutical companies - Market size and forecast 2023-2028
      • Chart on Startups and generic pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Startups and generic pharmaceutical companies - Market size and forecast 2023-2028 ($ billion)
      • Chart on Startups and generic pharmaceutical companies - Year-over-year growth 2023-2028 (%)
      • Data Table on Startups and generic pharmaceutical companies - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by End-user
      • Market opportunity by End-user ($ billion)
      • Data Table on Market opportunity by End-user ($ billion)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Chart on Product - Market share 2023-2028 (%)
      • Data Table on Product - Market share 2023-2028 (%)
    • 7.2 Comparison by Product
      • Chart on Comparison by Product
      • Data Table on Comparison by Product
    • 7.3 Tablets - Market size and forecast 2023-2028
      • Chart on Tablets - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Tablets - Market size and forecast 2023-2028 ($ billion)
      • Chart on Tablets - Year-over-year growth 2023-2028 (%)
      • Data Table on Tablets - Year-over-year growth 2023-2028 (%)
    • 7.4 Capsules - Market size and forecast 2023-2028
      • Chart on Capsules - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Capsules - Market size and forecast 2023-2028 ($ billion)
      • Chart on Capsules - Year-over-year growth 2023-2028 (%)
      • Data Table on Capsules - Year-over-year growth 2023-2028 (%)
    • 7.5 Powders - Market size and forecast 2023-2028
      • Chart on Powders - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Powders - Market size and forecast 2023-2028 ($ billion)
      • Chart on Powders - Year-over-year growth 2023-2028 (%)
      • Data Table on Powders - Year-over-year growth 2023-2028 (%)
    • 7.6 Granules and others - Market size and forecast 2023-2028
      • Chart on Granules and others - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Granules and others - Market size and forecast 2023-2028 ($ billion)
      • Chart on Granules and others - Year-over-year growth 2023-2028 (%)
      • Data Table on Granules and others - Year-over-year growth 2023-2028 (%)
    • 7.7 Market opportunity by Product
      • Market opportunity by Product ($ billion)
      • Data Table on Market opportunity by Product ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Chart on Market share by geography 2023-2028 (%)
      • Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Chart on Geographic comparison
      • Data Table on Geographic comparison
    • 9.3 Asia - Market size and forecast 2023-2028
      • Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.4 North America - Market size and forecast 2023-2028
      • Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Chart on North America - Year-over-year growth 2023-2028 (%)
      • Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.5 Europe - Market size and forecast 2023-2028
      • Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 China - Market size and forecast 2023-2028
      • Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Chart on China - Year-over-year growth 2023-2028 (%)
      • Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.8 US - Market size and forecast 2023-2028
      • Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Chart on US - Year-over-year growth 2023-2028 (%)
      • Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.9 Japan - Market size and forecast 2023-2028
      • Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Chart on Canada - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
      • Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 Germany - Market size and forecast 2023-2028
      • Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Market opportunity by geography ($ billion)
      • Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Opportunity/Restraints

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market opportunities/restraints

          11 Competitive Landscape

          • 11.1 Overview
            • 11.2 Competitive Landscape
              • Overview on criticality of inputs and factors of differentiation
            • 11.3 Landscape disruption
              • Overview on factors of disruption
            • 11.4 Industry risks
              • Impact of key risks on business

            12 Competitive Analysis

            • 12.1 Companies profiled
              • Companies covered
            • 12.2 Market positioning of companies
              • Matrix on companies position and classification
            • 12.3 AbbVie Inc.
              • AbbVie Inc. - Overview
              • AbbVie Inc. - Product / Service
              • AbbVie Inc. - Key news
              • AbbVie Inc. - Key offerings
            • 12.4 Aenova Holding GmbH
              • Aenova Holding GmbH - Overview
              • Aenova Holding GmbH - Product / Service
              • Aenova Holding GmbH - Key offerings
            • 12.5 Boehringer Ingelheim International GmbH
              • Boehringer Ingelheim International GmbH - Overview
              • Boehringer Ingelheim International GmbH - Product / Service
              • Boehringer Ingelheim International GmbH - Key news
              • Boehringer Ingelheim International GmbH - Key offerings
            • 12.6 Catalent Inc.
              • Catalent Inc. - Overview
              • Catalent Inc. - Business segments
              • Catalent Inc. - Key offerings
              • Catalent Inc. - Segment focus
            • 12.7 Corden Pharma International GmbH
              • Corden Pharma International GmbH - Overview
              • Corden Pharma International GmbH - Product / Service
              • Corden Pharma International GmbH - Key offerings
            • 12.8 Jubilant Pharmova Ltd.
              • Jubilant Pharmova Ltd. - Overview
              • Jubilant Pharmova Ltd. - Business segments
              • Jubilant Pharmova Ltd. - Key news
              • Jubilant Pharmova Ltd. - Key offerings
              • Jubilant Pharmova Ltd. - Segment focus
            • 12.9 Lonza Group Ltd.
              • Lonza Group Ltd. - Overview
              • Lonza Group Ltd. - Business segments
              • Lonza Group Ltd. - Key news
              • Lonza Group Ltd. - Key offerings
              • Lonza Group Ltd. - Segment focus
            • 12.10 Merck KGaA
              • Merck KGaA - Overview
              • Merck KGaA - Business segments
              • Merck KGaA - Key news
              • Merck KGaA - Key offerings
              • Merck KGaA - Segment focus
            • 12.11 NextPharma GmbH
              • NextPharma GmbH - Overview
              • NextPharma GmbH - Product / Service
              • NextPharma GmbH - Key offerings
            • 12.12 Perkin Elmer Inc.
              • Perkin Elmer Inc. - Overview
              • Perkin Elmer Inc. - Business segments
              • Perkin Elmer Inc. - Key news
              • Perkin Elmer Inc. - Key offerings
              • Perkin Elmer Inc. - Segment focus
            • 12.13 Piramal Enterprises Ltd.
              • Piramal Enterprises Ltd. - Overview
              • Piramal Enterprises Ltd. - Product / Service
              • Piramal Enterprises Ltd. - Key offerings
            • 12.14 Pyramid Laboratories Inc.
              • Pyramid Laboratories Inc. - Overview
              • Pyramid Laboratories Inc. - Product / Service
              • Pyramid Laboratories Inc. - Key offerings
            • 12.15 Recipharm AB
              • Recipharm AB - Overview
              • Recipharm AB - Business segments
              • Recipharm AB - Key offerings
              • Recipharm AB - Segment focus
            • 12.16 Siegfried Holding AG
              • Siegfried Holding AG - Overview
              • Siegfried Holding AG - Business segments
              • Siegfried Holding AG - Key offerings
              • Siegfried Holding AG - Segment focus
            • 12.17 Thermo Fisher Scientific Inc.
              • Thermo Fisher Scientific Inc. - Overview
              • Thermo Fisher Scientific Inc. - Business segments
              • Thermo Fisher Scientific Inc. - Key news
              • Thermo Fisher Scientific Inc. - Key offerings
              • Thermo Fisher Scientific Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Inclusions checklist
                • Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Currency conversion rates for US$
              • 13.4 Research methodology
                • Research methodology
              • 13.5 Data procurement
                • Information sources
              • 13.6 Data validation
                • Data validation
              • 13.7 Validation techniques employed for market sizing
                • Validation techniques employed for market sizing
              • 13.8 Data synthesis
                • Data synthesis
              • 13.9 360 degree market analysis
                • 360 degree market analysis
              • 13.10 List of abbreviations
                • List of abbreviations

              Research Methodology

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              Interested in this report?

              Get your sample now to see our research methodology and insights!

              Download Now

              Frequently Asked Questions

              Oral Solid Dosage (OSD) Contract Manufacturing market growth will increase by $ 14.2 bn during 2024-2028.

              The Oral Solid Dosage (OSD) Contract Manufacturing market is expected to grow at a CAGR of 6.84% during 2024-2028.

              Oral Solid Dosage (OSD) Contract Manufacturing market is segmented by End-user( Large-size companies, Small and medium size companies, Startups and generic pharmaceutical companies) Product( Tablets, Capsules, Powders, Granules and others)

              AbbVie Inc., Acino International AG, Aenova Holding GmbH, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Catalent Inc., Corden Pharma International GmbH, Inglasia Pharma Solutions, Jubilant Pharmova Ltd., Koninklijke DSM NV, Lonza Group Ltd., Merck KGaA, NextPharma GmbH, Perkin Elmer Inc., Piramal Enterprises Ltd., Pyramid Laboratories Inc., Recipharm AB, Siegfried Holding AG, Thermo Fisher Scientific Inc., Viatris Inc. are a few of the key vendors in the Oral Solid Dosage (OSD) Contract Manufacturing market.

              Asia will register the highest growth rate of 45% among the other regions. Therefore, the Oral Solid Dosage (OSD) Contract Manufacturing market in Asia is expected to garner significant business opportunities for the vendors during the forecast period.

              China, US, Japan, Canada, Germany

              • Patent expiry and increasing demand for generic drugsGenerics are low-cost drugs that have therapeutic safety and effectiveness characteristics similar to branded versions. One of the primary factors fueling the expansion of the generic drugs industry is the increasing pressure to reduce rising healthcare costs. Considering the need to reduce the cost of healthcare is the driving factor this market.
              • governments all over the world are promoting the use of generic medications. The expiry of the patents on various branded medications is another key reason fueling the expansion of the generic drugs industry. In emerging markets such as South Korea is the driving factor this market.
              • around 51 patents is the driving factor this market.
              • which cover more than 150 pharmaceutical products is the driving factor this market.
              • are scheduled to expire in 2023. Although the patent cliff has resulted in significant income and volume losses for branded drug manufacturers is the driving factor this market.
              • the expiry of patents allows multiple low-cost generic equivalents to enter the market is the driving factor this market.
              • which will ultimately lead to a higher volume of drugs sold. This is a positive indication for industry expansion because generic drug manufacturers outsource around 80% of their production to CMOs. These factors are expected to drive the growth of the global oral solid dosage (OSD) contract manufacturing market during the forecast period. is the driving factor this market.

              The Oral Solid Dosage (OSD) Contract Manufacturing market vendors should focus on grabbing business opportunities from the Large-size companies segment as it accounted for the largest market share in the base year.